Shire plc

Shire posts upbeat guidance despite being jilted by AbbVie

Published: 08:57, October 24, 2014

Dublin based pharmaceutical multinational Shire plc raised its 2014 guidance on Friday, despite being jilted by AbbVie on a $55 billion acquisition deal earlier this week.

Shire’s shares were up by 2.5% in early trading in London on Friday after taking a nosedive following AbbVie’s decision to abandon the merger deal.

AbbVie decided not to go ahead with Shire’s acquisition after the US Treasury Department cracked down tax inversion, i.e. it is no longer as advantageous for US-based companies to make merger deals with foreign companies and move their HQ abroad.

Shire’s third-quarter earnings per ADS jumped 60% to $2.93 on revenue of $1.6 billion, which had grown by nearly one third.

The company, which is listed in the London Stock Exchange as well as Nasdaq, forecasts full-year earnings growth in the high 30% range, compared to its July’s prediction which was in the low-to-mid 30% range.

Flemming Ornskov, Shire CEO

Flemming Ornskov believes Shire has an excellent future as a standalone company.

Shire’s Chairman, Susan Kilsby, commented:

“Shire is well-positioned for future growth as we implement our plan to double product sales to $10 billion by 2020. I am confident that Shire, as an independent company, will deliver long-term value to our shareholders and improved outcomes for patients. On behalf of the Board of Directors, I would like to thank the Shire management team and employees for the achievement of outstanding financial results during the third quarter.”

Flemming Ornskov, M.D., Shire’s Chief Executive Officer, said the company’s strong third quarter result is an example of its exceptional track record at delivering value and growth for shareholders.

Dr. Ornskov says sales have increased across its portfolio, with all its top-ten medications delivering double-digit growth in Q3 2014.

Shire’s largest business unit, Rare Diseases, saw sales increase by 66%, partly driven by the acquisition of ViroPharma.

Hereditary angioedema drug Cinryze achieved sales of $145 million, while Firazyr (also for treating hereditary angioedema) saw sales increase by 57%.

ADHD medication Vyvanse sales grew by 19% and those of inflammatory bowel disease drug Lialda were 24% up.

Veronica Salvador Avatar

Other News

Personalized AI video ads drew more clicks in a WhatsApp experiment

Nov 19, 2026

Restaurant advertising results can depend on an existing reputation

Nov 19, 2026

Search suggestions can help shoppers find less familiar products

Nov 19, 2026

AI-generated shoppers can give misleading pricing estimates, study finds

Nov 19, 2026

The design of a discount label can change how shoppers judge an offer

Nov 19, 2026

What virtual shopping tools can change before and after a purchase

Nov 19, 2026

Game-like loyalty features drew more engagement in an online grocery study

Nov 18, 2026

A delivery cue helped more shoppers move to the next checkout step

Nov 18, 2026

Small changes in a store can bring promotions back to repeat customers’ attention

Nov 18, 2026

Some sellers accept less when a buyer shares an item’s heritage

Nov 18, 2026

Changing a marketplace trust badge can change what sellers prioritize

Nov 18, 2026

Referred customers may bring in more customers of their own

Nov 18, 2026

An extra option can make an attractive menu less appealing, experiments find

Nov 17, 2026

Adding similar choices can change which products look like the middle option

Nov 17, 2026

World Bank plans e-commerce pilot for small firms in three West African countries

Nov 17, 2026

Contextual ads were the most common targeting method among EU online advertisers

Nov 17, 2026

People treat the same money differently across spending categories, study finds

Nov 17, 2026

Small-business loan applications can stall before they are formally submitted

Nov 17, 2026

Describing the parts of an experience can change how much people enjoy it

Nov 16, 2026

A prize can feel different when customers know they might have received less

Nov 16, 2026